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Purpose: We aimed to determine whether 12 core-extended biopsies of the pros-
tate could predict insignificant prostate cancer (IPCa) in Koreans reliably enough 
to recommend active surveillance. Materials and Methods: Two hundred and 
ninety-seven patients who underwent radical prostatectomy after 12 core-extended 
prostate biopsies were retrospectively reviewed. 38 cases (12.8%) were shown to 
be IPCa. Results: The average age was 65.2 years, serum PSA was 5.49 ng/dL, 
and the PSA density was 0.11. The Gleason scores (GS) were 6 (3+3) in 31, 5 
(3+2) in 4, and 4 (2+2) in 3. After radical prostatectomy, higher GS was given in 
16 (42.1%), whereas lower GS was given in 1 case (2.6%), as compared with the 
GS obtained from biopsy. 11 (28.9%) had GS of 7 (3+4) and 5 (13.2%) had GS of 
7 (4+3). 6 in GS 7 (4+3) and 1 in GS 7 (3+4) showed prostate capsule invasion 
and 1 in GS 7 (4+3) had seminal vesicle invasion. Prostate capsule invasion was 
observed in 1 with GS 6 (3+3). The rate of inaccuracy of the contemporary Ep-
stein criteria was 42.1%. Only PSA density was a reliable indicator of clinically 
IPCa (odds ratio=1.384, 95% CI, 1.103 to 2.091). Conclusion: Diagnosis of IPCa 
from a prostate biopsy underestimated the true nature of prostate cancer in as 
many as 42.1% of Koreans.
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INTRODUCTION
Recently, prostate specific antigen (PSA) screening for prostate cancer has become 
common, and the prostate biopsy technique has evolved, increasingly detecting 
clinically insignificant prostate cancer.1,2 However, there is no precise guideline for 
managing clinically insignificant prostate cancer (IPCa) with an early diagnosis. 
The Epstein criteria is the most frequently used set of definitions for determining 
whether prostate cancer is clinically insignificant, and this criteria are the basis for 
starting active surveillance.3,4 However, there are some reports that the reliability 
of the Epstein criteria can vary by race or regions. This implies that the significance 
of the Epstein criteria can be different between Western and Asian men.5 Some au-
thors have reported that the Epstein criteria may be inaccurate in Asians with pros-
tate cancer. They reported that there was higher negative predictive value when the Are IPCa Really Insignificant in Korean Men?
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and designated as either right or left standard sextant or lat-
eral peripheral zone biopsy cores.9
Pathology
The pathologic grading was done according to the Gleason 
scoring system, and the pathologic review was performed 
by a single experienced urologic pathologist (S.W.H.). The 
prostatectomy specimens were fixed overnight (10% neutral 
buffered formaldehyde) and coated with India ink. Trans-
verse whole mount step section specimens were obtained at 
4 mm intervals on a plane. The presence and extent of can-
cer were outlined on the glass cover. The presence of tumor 
cells beyond the capsular margin was defined as extracapsu-
lar extension. The largest tumor nodule was mapped and 
categorized according to grade, location, volume, pathologic 
stage and margin status. The volume was calculated using a 
computer assisted image analysis system.10
Statistics
Statistical analyses were performed using Student’s t-test to 
evaluate the demographic and clinical differences between 
IPCa and significant PCa groups. Multivariate analysis was 
performed to determine the independent prognostic factors 
for IPCa. A chi-square test was used to compare groups for 
categorical variables, and a p value of <0.05 was consid-
ered significant. 
 
RESULTS
 
Of the 297 cases, 38 (12.8%) were found to be IPCa. The 
average age was 65.2 years, average serum PSA was 5.49 
ng/dL, and average PSA density was 0.11. Table 1 shows 
the differences in preoperative clinical variables between the 
IPCa and significant PCa groups. The mean PSA and PSA 
density were 5.49 ng/mL and 0.11 in the IPCa group and 
9.91 ng/mL and 0.42 in the significant PCa group (p=0.012, 
0.027, respectively). After a radical prostatectomy, an up-
graded Gleason score was found in 16 cases (42.1%) where-
as a downgraded Gleason score occurred in 1 case (2.6%), 
when compared with the Gleason score from the biopsy 
(Table 2). Eleven cases (28.9%) of Gleason score 7 (3+4) 
and five cases (13.2%) of Gleason score 7 (4+3) were ob-
served. Six cases of Gleason score 7 (3+4) and one case of 
Gleason score 7 (4+3) showed prostate capsule invasion 
and one case of Gleason score 7 (4+3) had seminal vesicle 
invasion. The inaccuracy of the contemporary Epstein crite-
Epstein criteria were applied to IPCa patients in Asia than 
in any other country.6,7 Our aim was to determine whether 
12 core-extended biopsies of the prostate could reliably 
predict IPCa in men who were candidates for watchful 
waiting. Our aim was also to determine trends in the inci-
dence of IPCa after prostate biopsies and pathology up-
grade after radical prostatectomy.
MATERIALS AND METHODS
　　　
Overview
Two hundred and ninety-seven patients who had undergone 
a radical prostatectomy after 12-core transrectal ultrasonog-
raphy-guided prostatic biopsies between January 2004 and 
December 2009 at our institution were enrolled for a retro-
spective analysis. Before initiating this study, we obtained 
approval from the institutional review board. We reviewed 
the specimens from prostatic biopsies and radical prostatec-
tomies that had been performed in 2004 through to 2005 
(group 1), 2006 through to 2007 (group 2), and 2008 
through to 2009 (group 3). According to the Epstein crite-
ria, IPCa was defined as a PSA density of less than 0.15 ng/
dL, a biopsy Gleason score ≤6, less than or equql to 2 posi-
tive cores in 6 core biopsies, and a single core percentage 
under 50%.4,8 We excluded patients who had undergone 
prostate biopsy at other institution, hormone therapy or radi-
ation therapy before the radical prostatectomy. The radical 
prostatectomy was performed by a single surgeon (B.H.C.).
Biopsy protocol 
A kit from BK Medical, Denmark was used for prostatic bi-
opsies (right 6 cores and left 6 cores). The 12-core biopsies 
were done in each patient by a urologist with 12 years of 
experience. According to the standard of previous biopsy 
protocol, sextant biopsy was performed from the apex, mid, 
and base of the right and left parasagittal planes of the pros-
tate including an additional 3 cores from the peripheral zone 
positioned more laterally on each side.8 Biopsy was per-
formed either under local anesthesia or general anesthesia 
and 12 cores were obtained regardless of prostate volume. 
In cases under anesthesia, patients required a 3-5 day ad-
ministration of fluoroquinolone and midnight NPO from 
the day before biopsy was performed, usually followed by 
a 3-5 day course of antibiotic treatment. The standard length 
of the biopsy cores was 15 mm, and each core was embed-
ded separately. They were divided in multiple containers, Chan Dong Yeom, et al.
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tively]. In the logistic regression analysis, only PSA density 
was found to be a predictable indicator for clinically IPCa 
(odds ratio=1.384, 95% CI, 1.103 to 2.091) (Table 3).
DISCUSSION
The contemporary Epstein criteria are the most widely used 
tool for predicting clinically IPCa.4,11 One study reported 
that the accuracy of the Epstein criteria in the USA was 84%, 
ria was 42.1%. 
The incidence of IPCa after prostate biopsy showed a pat-
tern of increase over time, especially in group 3. The propor-
tion of IPCa was 8/81 cases (10.1%) in group 1, 10/94 cas-
es in group 2 (10.6%), and 20/122 cases in group 3 (16.4%) 
(Fig. 1). However, there was no change of incidence with 
time to upgrade from IPCa to significant PCa after radical 
prostatectomy [3/8 cases (37.5%) in group 1, 5/10 cases 
(50%) in group 2, and 8/20 cases (40%) in group 3, respec-
Table 1. Preoperative Clinical Tumor Characteristics of Prostate Cancer Patients 
Variables Insignificant prostate cancer (n=38) Significant prostate cancer (n=259) p value
Mean age (yrs) 65.2 (43-71) 66.4 (48-74) 0.411
Prostate volume (cc) 35.5 (16-76)   34.4 (14-123) 0.285
Preoperative PSA (nL/mL)*       5.49 (2.51-11.8)         9.91 (3.08-19.73) 0.012
PSA density (ng/mL)*       0.11 (0.07-0.34)       0.42 (0.10-0.73) 0.027
Bx Gleason sum (mean)*
†      5.7        6.9 0.043
<6    7     2
6  31   97
>6    0 158
% of positive cores (means)*    20.0      66.3 0.002
No of positive cores (means)*
†      2.2         3.3 0.016
1 13   27
2 11   74
3   8   77
4   6   31
5 or more   0   48
PSA, prostate specific antigen.
The parenthesis for age, prostate volume, preoperative PSA, PSA density are range. 
*p<0.05 by Student’s t-test.
†p<0.05 by chi square test.
Table 2. Pathological Findings from Analyses of Prostatec-
tomy Specimens which Fulfilled the Epstein Clinically Insig-
nificant Prostate Cancer Criteria
Pathologic findings (n)
SM+ 5 (13.2%)
Organ confined disease 34
Non organ confined disease
ECE   3
SVI   1
LNI   0
Pathologic Gleason sum
    <6   4
    6 18
    7 (3+4) 11
    7 (4+3)   5
Gleason sum upgrading   16 (42.11%)
Tumor volume (cc) 0.27
    >0.5   5 (17.2%)
    <0.5 33 (86.8%)
SM, surgical margin; ECE, extracapsular extension; SVI, seminal vesicle 
invasion; LNI, lymph node invasion.
Table 3. The Results of the Multiple Logistic Regression 
Analysis to Test the Predictable Indicator for Clinically Insig-
nificant Prostate Cancer 
Variable Odds ratio (95% CI) p value
Age (yrs) 1.034 (0.843-3.117) 0.581
BMI (kg/m
2) 1.058 (0.722-1.138) 0.517
PSA 1.293 (0.932-1.354) 0.067
PSA density 1.384 (1.103-2.091) 0.041
Biopsy Gleason sum
    Gleason scores ≤6 Reference
    Gladeason socres >6 0.948 (0.467-1.319) 0.815
% of positive cores in a  
  biopsy 0.782 (0.501-1.021) 0.355
No of positive cores 0.791 (0.091-2.312) 0.518
Prostate volume 1.141 (0.735-1.559) 0.329
Clinical T stage
≤T2 Reference
T3≤ 0.931 (0.482-1.712) 0.381
BMI, body mass index; PSA, prostate specific antigen.Are IPCa Really Insignificant in Korean Men?
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tectomy. However, Chun, et al.19 found that the rate of up-
grading decreased over time, from 52% to 27%, between 
1992 and 2004. These contradictory results might result not 
only from different races, more aggressive tumor character-
istics as compared to Western men,12 and environmental 
conditions, but also from the study design. Our study was 
carried out by a single surgeon and a single pathologist at a 
single institute, therefore, the quality of the data may be 
more homogenous than previous studies. 
Because the incidence and mortality of PCa differ accord-
ing to race and dietary habits, the accuracy of the Epstein 
criteria of studies in Asian countries is unlikely to be as ac-
curate as other countries. This is very meaningful in deter-
mining the early stage treatment of PCa after a prostatic bi-
opsy. Recently, there have been various treatment options 
developed for early prostate cancer, such as active surveil-
lance, surgical treatment or radiation therapy.20 The optimal 
treatment of early PCa has been controversial; however, our 
present results indicate that caution should be advised when 
treatment decisions are based solely on the Epstein criteria, 
especially in Korea.
This study has several limitations. First, this is a retro-
spective study with a relatively small number of patients en-
rolled, as it was conducted at a single institution. However, 
it should be noted that our cohort from a single surgeon 
may elevate the reliability of the results. Furthermore, con-
sidering the large difference in prostate cancer incidence 
between Korean and Western men, the number of men in 
the present series should not be considered too small for a 
single institution.6 Furthermore, as follow up was limited, 
we could not assess the biochemical recurrence or progno-
sis, which may be a more important issue than the presence 
of unfavorable pathological features.6 Further investigation 
and that they underestimated the disease stage and/or grade 
in 16% of USA patients.4 Another study reported that 24% 
of male European patients who fulfilled the Epstein criteria 
for presence of clinically insignificant prostate cancer were 
incorrectly classified as having clinically IPCa.12 Gleason 
7-10 prostate cancer at radical prostatectomy was found in 
24% patients with clinically IPCa. The pathological charac-
teristics of these 24% might actually represent an absolute 
contraindication to active surveillance or similar treatment 
modalities that are usually applicable for men with clinical-
ly IPCa. Lee, et al.6 reported an inaccuracy of the Epstein 
criteria of up to 30.5% in Korea. In our study, the inaccura-
cy of the Epstein criteria of our study was 42.1% and this 
is, to our knowledge, the highest reported value. This high 
inaccuracy rate of the Epstein criteria might be due to more 
aggressive and poorly differentiated prostate cancer in Ko-
rean men, despite a low clinical stage or low serum PSA 
level.13 Also, Man, et al.14 reported that a greater proportion 
of Asian patients present high risk prostate cancer than non 
Asian men. There were twice the percentage of Asian pa-
tients with Gleason scores 8 or greater than nonAsians at 
presentation. Prostate cancer of predominantly high grade 
in Korean men may be attributed to reduced testosterone 
metabolism. Hoffman, et al.15 illustrated that patients with a 
low serum-free testosterone level have an increased mean 
percentage of biopsies revealing cancer with a Gleason 
score of 8 or higher, suggesting that a low serum-free tes-
tosterone level may be a marker of more aggressive disease. 
In our current study, however, we are not certain whether 
there exists a relationship between aggressiveness of PCa 
and serum testosterone level. This hypothesis should be in-
vestigated in a future study. 
In our study, PSA density was found to be a prognostic 
factor for clinically IPCa. The incidence of prostate cancer 
in the low PSA (2.5-4.0) group was reported to be more than 
20% in Korea.16 Furthermore, PCa detected by biopsies with 
low PSA levels have been shown to be clinically significant, 
and there are no differences in pathologic stage and Gleason 
pattern between the preoperative low PSA and high PSA 
groups after radical prostatectomy.16-18 This implies that 
there are no definite preoperative variables for a diagnosis of 
clinically IPCa, thus confusing the diagnosis and treatment. 
Additional novel markers might be needed in order to ele-
vate the predictive accuracy of the Epstein criteria.
Besides the high inaccuracy rate of the Epstein criteria in 
our study, the criteria showed no change of incidence of an 
upgrade from IPCa to significant one after radical prosta-
0
5
10
15
20
25
30
35
40
45
50
2004-2005 2006-2007 2008-2009
  Upgrading      IPCa
Fig. 1. Incidence of insignificant prostate cancer after prostate biopsy and 
upgraded pathology after radical prostatectomy. IPCa, insignificant pros-
tate cancer.Chan Dong Yeom, et al.
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is needed for the development of more accurate diagnostic 
tool of identifying Asian men with clinically IPCa. 
The incidence of IPCa after prostate biopsy showed an 
increase with time. However, the Epstein criteria may not 
be validly applicable in Korean PCa patients because the 
inaccuracy rate of the criteria was as high as 42.1%. A modi-
fied diagnostic tool for active surveillance is necessary for 
Korean PCa patients. 
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